ATROPOS: Survival Analysis of ICI-associated Myocarditis
Key facts
- Where
- Paris, FranceSee the site
Where in France
- Hopital Pitie-Salpetriere / CIC-2503Paris, FranceContact: Joe-Elie Salem, MD-PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Groupe Hospitalier Pitie-Salpetriere
- Trial code
- NCT07633587
- Record updated
- 10 June 2026
- Original description
ATROPOS is an international, registry-based observational study of cancer patients with immune checkpoint inhibitor-associated myocarditis (ICI-M). The study evaluates whether immunosuppressive treatment strategies, including first-line glucocorticoids and subsequent second-line immunosuppressants, are associated with overall mortality, and whether these associations vary according to myocarditis severity. The target number of cases to be included is 1500 spanning from at least 160 centers, located in at least 18 countries. Analyses will adjust for clinically relevant confounders and may use time-dependent survival models where appropriate.Read full original descriptionShow less
ATROPOS: Assessing morTality and Risk factOrs in Immune checkPoint Inhibitor-induced myotOxicities: a Survival Analysis Based on an International Registry
ATROPOS is an international, registry-based observational study of cancer patients with immune checkpoint inhibitor-associated myocarditis (ICI-M). The study evaluates whether immunosuppressive treatment strategies, including first-line glucocorticoids and subsequent second-line immunosuppressants, are associated with overall mortality, and whether these associations vary according to myocarditis severity. The target number of cases to be included is 1500 spanning from at least 160 centers, located in at least 18 countries. Analyses will adjust for clinically relevant confounders and may use time-dependent survival models where appropriate.
Inclusion: cancer patients exposed to at least one immune checkpoint inhibitor; possible, probable or definite immune checkpoint inhibitor-associated myocarditis recorded in the international registry according to registry/adjudication definitions; available index-date/presentation information; available mortality follow-up.
Exclusion: duplicate records; not enough data to classify as myocarditis; record/patient withdrawn from research use unresolved data-quality issues preventing inclusion in the final SAP-defined analysis set.